Tandem Diabetes Care has launched its latest automated insulin delivery technology, Control-IQ+, in the US.
This advanced hybrid closed-loop algorithm is designed to cater to individuals with type 1 diabetes aged two years and above, as well as adults with type 2 diabetes. The technology is integrated into the t:slim X2 insulin pump and the Tandem Mobi System, with new pumps shipping to customers pre-loaded with the software.
Current Tandem customers with in-warranty devices can upgrade to the new software remotely at no additional cost.
The Control-IQ+ technology includes several new features to enhance user experience and diabetes management. It supports a broader range of body weights (20-440 lbs.) and total daily insulin requirements (5-200 units), making it more accessible to diverse patients.
The algorithm also offers an enhanced extended bolus feature for up to eight hours, aiding in the management of meals that result in delayed glucose increases or are consumed over extended periods. Additionally, users can make temporary basal rate adjustments to cater to short-term glucose fluctuations due to exercise, stress, or illness, even while the Control-IQ+ function is active.
Building upon Tandem’s Control-IQ algorithm, Control-IQ+ continues to adjust insulin delivery every five minutes based on predicted glucose levels. It also retains the unique AutoBolus feature, which automatically calculates and administers correction boluses for unaccounted mealtime insulin.
Tandem Diabetes Care president and CEO John Sheridan said: “These new features allow for even greater levels of personalisation and flexibility within our algorithm, while still receiving high marks for ease of use across a diverse population of users.
“We are proud to offer this life-changing technology to millions more people living with diabetes.”
In January this year, Tandem Diabetes Care partnered with the UVA Centre for Diabetes Technology to enhance insulin delivery.
